Valuation : Unicycive Therapeutics, Inc.

Market Cap 140M 121M 114M 103M 194M 13.33B 194M 1.35B 520M 6.79B 526M 515M 21.52B P/E 2026 *
-4.16x
P/E 2027 * 3.12x
Enterprise Value 140M 121M 114M 103M 194M 13.33B 194M 1.35B 520M 6.79B 526M 515M 21.52B EV / Sales 2026 *
509x
EV / Sales 2027 * 0.96x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * 41.4%
1 day+1.29%
1 week-1.64%
Current month-1.83%
1 month+1.69%
3 months-29.78%
6 months-27.59%
Current year-11.53%
1 week 5.01
Extreme 5.01
5.34
1 month 4.92
Extreme 4.915
5.85
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
31.9
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 2016-08-17
Director of Finance/CFO 64 2021-02-28
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Chairman 53 2016-08-17
Director/Board Member 58 2017-12-31
Director/Board Member 58 2023-09-05
Date Insider Type Main position Quantity % Market Cap. Importance
5/14/26 Free

Chief Operating Officer

169,500 0.6716%
5/14/26 Free

Executive/Senior Manager

169,500 0.6716%
5/14/26 Free

Chief Financial Officer

169,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
+1.29%-1.64%+16.55%-28.70% 140M
-0.94%+0.31%+40.04%+103.25% 69.19B
-0.07%-3.93%+32.54%+75.96% 62.97B
+4.30%+1.95%-12.30%+387.17% 27.27B
-1.07%-6.20%-4.62%-17.45% 24.78B
-0.93%-1.29%+25.30%+16.70% 25.8B
-1.43%-1.89%+21.32%-17.67% 20.11B
-4.27%+2.67%+219.02%+362.48% 18.47B
-1.43%-1.80%-8.64%+537.09% 14.88B
-0.01%-1.54%+50.55%+162.07% 14.29B
Average -0.43%-0.32%+37.97%+158.09% 27.79B
Weighted average by Cap. -0.45%-0.76%+36.31%+140.79%

Financials

2026 *2027 *
Net sales 275K 237K 223K 203K 380K 26.2M 382K 2.64M 1.02M 13.35M 1.03M 1.01M 42.29M 145M 125M 118M 107M 201M 13.84B 202M 1.4B 540M 7.05B 546M 534M 22.33B
Net income -34.12M -29.36M -27.64M -25.19M -47.13M -3.25B -47.32M -328M -127M -1.65B -128M -125M -5.24B 46.27M 39.81M 37.49M 34.16M 63.91M 4.4B 64.16M 444M 172M 2.24B 174M 170M 7.11B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
26-09-09 $5.105 +1.49% 559,829
26-09-08 $5.030 -2.52% 817,178
26-09-04 $5.160 -2.64% 492,881
26-09-03 $5.300 +2.12% 836,925
26-09-02 $5.190 +2.77% 760,474
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.030USD
Average target price
28.22USD
Spread / Average Target
+461.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!